- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04350476
COVID-19 Remote Monitoring
Remote Monitoring in Patients With Coronavirus Disease (COVID-19)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients diagnosed with coronavirus and determined to be eligible for home monitoring and self-care, and either
- Not admitted to the hospital, and permitted to recover at home
- Discharged from inpatient hospitalization, during the acute recovery period
- 18 years old or older with the ability to understand the requirements of the study and sign the informed consent form (or able to provide over-the-phone verbal consent).
Exclusion Criteria:
N/A
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Vital Connect Patch Arm
This is a non-randomized study. Based on clinical assessment, patients will be provided with the following home monitoring system: VitalConnect Vital Sign Patch (FDA approved for this indication) |
This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days. This patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of different arrhythmias
Time Frame: 7-14 Days
|
ac rhythm in patients with COVID-19 infection following treatment/discharge from MSH
|
7-14 Days
|
|
Temperature
Time Frame: 7-14 Days
|
Temperature of patients with COVID-19 infection following treatment/discharge from MHS
|
7-14 Days
|
|
Oxygen Saturation
Time Frame: 7-14 Days
|
Oxygen saturation level in patients with COVID-19 infection following treatment/discharge from MSH
|
7-14 Days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Arrhythmias, Cardiac
Other Study ID Numbers
- GCO 20-0932
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
PfizerActive, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionUnited States
-
Shanghai Public Health Clinical CenterNot yet recruiting
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RecruitingPost COVID-19 Condition | Post COVID-19 | Post COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID-19 Condition (PCC)Germany
-
PfizerRecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionBelgium
-
ModeX Therapeutics, An OPKO Health CompanyRecruitingCOVID -19 | COVID-19 (Prevention)United States
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID ConditionCanada
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
University of Missouri, Kansas CityNational Institute on Minority Health and Health Disparities (NIMHD)Active, not recruitingCOVID-19 Testing BehaviorsUnited States
Clinical Trials on VitalConnect Vital Sign Patch
-
The University of Texas Health Science Center,...Masimo CorporationNot yet recruiting
-
University of OxfordActive, not recruitingAtrial Fibrillation | Atrial Fibrillation New Onset | New Onset Atrial FibrillationUnited Kingdom
-
Universitätsklinikum Hamburg-EppendorfRecruitingVital Sign Monitoring | Non-cardiac Surgery | Anesthesiology | Post Operative Complications | RCTGermany
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeRecruitingPreterm Infant | Low; Birthweight, Extremely (999 Grams or Less) | Infant, NewbornUnited Kingdom
-
Bispebjerg HospitalActive, not recruitingRemote Monitoring | Vital Signs Monitoring | Hospital at Home | Continuous MonitoringDenmark
-
University Health Network, TorontoCompletedBlood Pressure, Heart Rate, Breathing Rate and Oxygen LevelCanada
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingPrematurityUnited States
-
Catharina Ziekenhuis EindhovenEindhoven University of TechnologyCompletedVital Signs | Clinical DeteriorationNetherlands
-
Centre for Infectious Disease Research in ZambiaWellcome Trust; Neopenda, PBCCompleted
-
Rigshospitalet, DenmarkBispebjerg HospitalRecruitingSurgery-Complications | Medical ComplicationDenmark